Pulmonx Corporation (NASDAQ: LUNG) reported Q4 EPS of ($0.36), $0.05 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $19.27 million versus the consensus estimate of $18.24 million.

GUIDANCE:

Pulmonx Corporation sees FY2024 revenue of $81-84 million, versus the consensus of $78.932 million.

The Company expects gross margin for the full year 2024 to fall within the range of 74% to 75%.

Pulmonx expects total operating expenses for the full year 2024 to fall within the range of $132 million to $134 million, inclusive of approximately $30 million of non-cash stock-based compensation.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.